Miguel Moutinho

Miguel Moutinho

Auto-generated profile, based on publicly available information

Miguel Moutinho

School of Medicine, Indiana University, Indianapolis, USA

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 December 2024 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
MHMichael Thomas Heneka
Michael Thomas Heneka
WFWiesje M. van der Flier
Wiesje M. van der Flier
FJFrank Jessen
Frank Jessen
JHJeroen Hoozemanns
Jeroen Hoozemanns
DTDietmar Rudolf Thal
Dietmar Rudolf Thal
SRSean-Patrick Riechers
Sean-Patrick Riechers

23 March 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
MMMiguel Moutinho
Miguel Moutinho
SPShweta S. Puntambekar
Shweta S. Puntambekar
Andy P TsaiAndy P Tsai
Andy P Tsai
ICIsrael Coronel
Israel Coronel
PLPeter Bor-Chian Lin
Peter Bor-Chian Lin
GLGary E. Landreth
Gary E. Landreth
Increased dietary intake of niacin has been correlated with reduced risk of Alzheimer’s disease (AD). Niacin serves as a high-affinity ligand for the receptor HCAR2 (GPR109A). In the brain, HCAR2 is expressed selectively by microglia and is robustly induced by amyloid pathology in AD. The genetic inactivation of Hcar2 in 5xFAD mice, a model of AD, results in impairment of the microglial response to amyloid deposition, including deficits in gene expression, proliferation, envelopment of amyloid plaques, and uptake of amyloid-β (Aβ), ultimately leading to exacerbation of amyloid burden, neuronal loss, and cognitive deficits. In contrast, activation of HCAR2 with an FDA-approved formulation of niacin (Niaspan) in 5xFAD mice leads to reduced plaque burden and neuronal dystrophy, attenuation of neuronal loss, and rescue of working memory deficits. These data provide direct evidence that HCAR2 is required for an efficient and neuroprotective response of microglia to amyloid pathology. Administration of Niaspan potentiates the HCAR2-mediated microglial protective response and consequently attenuates amyloid-induced pathology, suggesting that its use may be a promising therapeutic approach to AD that specifically targets the neuroimmune response.

1 January 2012 in Frontiers in Cellular Neuroscience
Verified
Journal Article
Open access
PDF file
IPInês Palmela
Inês Palmela
HSHiroyuki Sasaki
Hiroyuki Sasaki
FCFilipa L. Cardoso
Filipa L. Cardoso
MMMiguel Moutinho
Miguel Moutinho
KKKwang Sik Kim
Kwang Sik Kim
MBMaria Brito
Maria Brito
In neonatal jaundice, high levels of unconjugated bilirubin (UCB) may induce neurological dysfunction (BIND). Recently, it was observed that UCB induces alterations on brain microvasculature, which may facilitate its entrance into the brain, but little is known about the steps involved. To evaluate if UCB damages the integrity of human brain microvascular endothelial cells (HBMECs), we used 50 or 100 μM UCB plus human serum albumin, to mimic the neuropathological conditions where levels of UCB free species correspond to moderate and severe neonatal jaundice, respectively. Our results point to a biphasic response of HBMEC to UCB depending on time of exposure. The early response includes increased number of caveolae and caveolin-1 expression, as well as upregulation of vascular endothelial growth factor (VEGF) and its receptor 2 (VEGFR-2) with no alterations of the paracellular permeability. In contrast, effects by sustained hyperbilirubinemia are the reduction in zonula occludens (ZO)-1 and β-catenin levels and thus of tight junctions (TJ) strands and cell-to-cell contacts. In addition, reduction of the transendothelial electrical resistance (TEER) and increased paracellular permeability are observed, revealing loss of the barrier properties. The 72 h of HBMEC exposure to UCB triggers a cell response to the stressful stimulus evidenced by increased autophagy. In this later condition, the UCB intracellular content and the detachment of both viable and non-viable cells are increased. These findings contribute to understand why the duration of hyperbilirubinemia is considered one of the risk factors of BIND. Indeed, facilitated brain entrance of the free UCB species will favor its parenchymal accumulation and neurological dysfunction.

20 February 2023 in Genome Medicine
Verified
Journal Article
Open access
PDF file
MMMiguel Moutinho
Miguel Moutinho
ICIsrael Coronel
Israel Coronel
ATAndy P. Tsai
Andy P. Tsai
GPGonzalo Viana Di Prisco
Gonzalo Viana Di Prisco
TPTaylor Pennington
Taylor Pennington
GLGary E. Landreth
Gary E. Landreth
Background: TREM2 is a transmembrane receptor expressed by myeloid cells and acts to regulate their immune response. TREM2 governs the response of microglia to amyloid and tau pathologies in the Alzheimer’s disease (AD) brain. TREM2 is also present in a soluble form (sTREM2), and its CSF levels fluctuate as a function of AD progression. Analysis of stroke and AD mouse models revealed that sTREM2 proteins bind to neurons, which suggests sTREM2 may act in a non-cell autonomous manner to influence neuronal function. sTREM2 arises from the proteolytic cleavage of the membrane-associated receptor. However, alternatively spliced TREM2 species lacking a transmembrane domain have been postulated to contribute to the pool of sTREM2. Thus, both the source of sTREM2 species and its actions in the brain remain unclear. Methods: The expression of TREM2 isoforms in the AD brain was assessed through the analysis of the Accelerating Medicines Partnership for Alzheimer’s Disease Consortium transcriptomics data, as well as qPCR analysis using post-mortem samples of AD patients and of the AD mouse model 5xFAD. TREM2 cleavage and secretion were studied in vitro using HEK-293T and HMC3 cell lines. Synaptic plasticity, as evaluated by induction of LTP in hippocampal brain slices, was employed as a measure of sTREM2 actions. Results: Three distinct TREM2 transcripts, namely ENST00000373113 (TREM2230), which encodes the full-length transmembrane receptor, and the alternatively spliced isoforms ENST00000373122 (TREM2222) and ENST00000338469 (TREM2219), are moderately increased in specific brain regions of patients with AD. We provide experimental evidence that TREM2 alternatively spliced isoforms are translated and secreted as sTREM2. Furthermore, our functional analysis reveals that all sTREM2 species inhibit LTP induction, and this effect is abolished by the GABAA receptor antagonist picrotoxin. Conclusions: TREM2 transcripts can give rise to a heterogeneous pool of sTREM2 which acts to inhibit LTP. These results provide novel insight into the generation, regulation, and function of sTREM2 which fits into the complex biology of TREM2 and its role in human health and disease. Given that sTREM2 levels are linked to AD pathogenesis and progression, our finding that sTREM2 species interfere with LTP furthers our understanding about the role of TREM2 in AD.

23 April 2013 in Purinergic Signalling
Verified
Journal Article
Closed access
PDF file
DTDominik Thimm
Dominik Thimm
MKMelanie Knospe
Melanie Knospe
AAAliaa Abdelrahman
Aliaa Abdelrahman
MMMiguel Moutinho
Miguel Moutinho
BABernt B. A. Alsdorf
Bernt B. A. Alsdorf
CMChrista Müller
Christa Müller